These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 21806349)

  • 1. Interim positron emission tomography scan associated with international prognostic index and germinal center B cell-like signature as prognostic index in diffuse large B-cell lymphoma.
    Lanic H; Mareschal S; Mechken F; Picquenot JM; Cornic M; Maingonnat C; Bertrand P; Clatot F; Bohers E; Stamatoullas A; Leprêtre S; Rainville V; Ruminy P; Bastard C; Tilly H; Becker S; Vera P; Jardin F
    Leuk Lymphoma; 2012 Jan; 53(1):34-42. PubMed ID: 21806349
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation of the STAT3 signaling pathway is associated with poor survival in diffuse large B-cell lymphoma treated with R-CHOP.
    Huang X; Meng B; Iqbal J; Ding BB; Perry AM; Cao W; Smith LM; Bi C; Jiang C; Greiner TC; Weisenburger DD; Rimsza L; Rosenwald A; Ott G; Delabie J; Campo E; Braziel RM; Gascoyne RD; Cook JR; Tubbs RR; Jaffe ES; Armitage JO; Vose JM; Staudt LM; McKeithan TW; Chan WC; Ye BH; Fu K
    J Clin Oncol; 2013 Dec; 31(36):4520-8. PubMed ID: 24220563
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 18F-FDG PET/CT for early response assessment in diffuse large B-cell lymphoma: poor predictive value of international harmonization project interpretation.
    Cashen AF; Dehdashti F; Luo J; Homb A; Siegel BA; Bartlett NL
    J Nucl Med; 2011 Mar; 52(3):386-92. PubMed ID: 21321279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of interim FDG-PET in diffuse large cell lymphoma: results from the CALGB 50303 Clinical Trial.
    Schöder H; Polley MC; Knopp MV; Hall N; Kostakoglu L; Zhang J; Higley HR; Kelloff G; Liu H; Zelenetz AD; Cheson BD; Wagner-Johnston N; Kahl BS; Friedberg JW; Hsi ED; Leonard JP; Schwartz LH; Wilson WH; Bartlett NL
    Blood; 2020 Jun; 135(25):2224-2234. PubMed ID: 32232481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The prognosis value of early and interim ¹⁸F-FDG-PET/CT scans in patients with diffuse large B-cell lymphoma].
    Zhang Y; Fan Y; Yang Z; Ying Z; Song Y; Zhu J; Wang X
    Zhonghua Xue Ye Xue Za Zhi; 2015 Oct; 36(10):824-9. PubMed ID: 26477759
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liquid biopsy for molecular characterization of diffuse large B-cell lymphoma and early assessment of minimal residual disease.
    Alcoceba M; Stewart JP; García-Álvarez M; Díaz LG; Jiménez C; Medina A; Chillón MC; Gazdova J; Blanco O; Díaz FJ; Peñarrubia MJ; Fernández S; Montes C; Cabero A; Caballero MD; García-Sanz R; González M; González D; Tamayo P; Gutiérrez NC; García-Sancho AM; Sarasquete ME
    Br J Haematol; 2024 Jul; 205(1):109-121. PubMed ID: 38811363
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Accurate classification of diffuse large B-cell lymphoma into germinal center and activated B-cell subtypes using a nuclease protection assay on formalin-fixed, paraffin-embedded tissues.
    Rimsza LM; Wright G; Schwartz M; Chan WC; Jaffe ES; Gascoyne RD; Campo E; Rosenwald A; Ott G; Cook JR; Tubbs RR; Braziel RM; Delabie J; Miller TP; Staudt LM
    Clin Cancer Res; 2011 Jun; 17(11):3727-32. PubMed ID: 21364035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimal timing and criteria of interim PET in DLBCL: a comparative study of 1692 patients.
    Eertink JJ; Burggraaff CN; Heymans MW; Dührsen U; Hüttmann A; Schmitz C; Müller S; Lugtenburg PJ; Barrington SF; Mikhaeel NG; Carr R; Czibor S; Györke T; Ceriani L; Zucca E; Hutchings M; Kostakoglu L; Loft A; Fanti S; Wiegers SE; Pieplenbosch S; Boellaard R; Hoekstra OS; Zijlstra JM; de Vet HCW
    Blood Adv; 2021 May; 5(9):2375-2384. PubMed ID: 33944897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. P38 MAPK expression and activation predicts failure of response to CHOP in patients with Diffuse Large B-Cell Lymphoma.
    Vega GG; Avilés-Salas A; Chalapud JR; Martinez-Paniagua M; Pelayo R; Mayani H; Hernandez-Pando R; Martinez-Maza O; Huerta-Yepez S; Bonavida B; Vega MI
    BMC Cancer; 2015 Oct; 15():722. PubMed ID: 26475474
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exploring the potential cost-effectiveness of precision medicine treatment strategies for diffuse large B-cell lymphoma.
    Chen Q; Staton AD; Ayer T; Goldstein DA; Koff JL; Flowers CR
    Leuk Lymphoma; 2018 Jul; 59(7):1700-1709. PubMed ID: 29065744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Are we ready to stratify treatment for diffuse large B-cell lymphoma using molecular hallmarks?
    Barton S; Hawkes EA; Wotherspoon A; Cunningham D
    Oncologist; 2012; 17(12):1562-73. PubMed ID: 23086691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transient expression of Bcl6 is sufficient for oncogenic function and induction of mature B-cell lymphoma.
    Green MR; Vicente-Dueñas C; Romero-Camarero I; Long Liu C; Dai B; González-Herrero I; García-Ramírez I; Alonso-Escudero E; Iqbal J; Chan WC; Campos-Sanchez E; Orfao A; Pintado B; Flores T; Blanco O; Jiménez R; Martínez-Climent JA; Criado FJ; Cenador MB; Zhao S; Natkunam Y; Lossos IS; Majeti R; Melnick A; Cobaleda C; Alizadeh AA; Sánchez-García I
    Nat Commun; 2014 Jun; 5():3904. PubMed ID: 24887457
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of subsequent PET/CT in diffuse large B-cell lymphoma patients in complete remission following primary therapy.
    Zhang X; Fan W; Xia ZJ; Hu YY; Lin XP; Zhang YR; Li ZM; Liang PY; Li YH
    Chin J Cancer; 2015 Feb; 34(2):70-8. PubMed ID: 25418196
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of super enhancer-associated key genes for prognosis of germinal center B-cell type diffuse large B-cell lymphoma by integrated analysis.
    Li X; Duan Y; Hao Y
    BMC Med Genomics; 2021 Mar; 14(1):69. PubMed ID: 33663517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting of inflammatory pathways with R2CHOP in high-risk DLBCL.
    Hartert KT; Wenzl K; Krull JE; Manske M; Sarangi V; Asmann Y; Larson MC; Maurer MJ; Slager S; Macon WR; King RL; Feldman AL; Gandhi AK; Link BK; Habermann TM; Yang ZZ; Ansell SM; Cerhan JR; Witzig TE; Nowakowski GS; Novak AJ
    Leukemia; 2021 Feb; 35(2):522-533. PubMed ID: 32139889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interleukin-4 distinctively modifies responses of germinal centre-like and activated B-cell-like diffuse large B-cell lymphomas to immuno-chemotherapy.
    Sarosiek KA; Nechushtan H; Lu X; Rosenblatt JD; Lossos IS
    Br J Haematol; 2009 Nov; 147(3):308-18. PubMed ID: 19694722
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cell of origin is not associated with outcomes of relapsed or refractory diffuse large B cell lymphoma.
    Desai SH; Mwangi R; Smith AN; Maurer MJ; Farooq U; King RL; Cerhan JR; Feldman AL; Habermann TM; Thompson CA; Wang Y; Ansell SM; Witzig TE; Nowakowski GS
    Hematol Oncol; 2023 Feb; 41(1):39-49. PubMed ID: 36305717
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances in biology, diagnosis and treatment of DLBCL.
    Shi Y; Xu Y; Shen H; Jin J; Tong H; Xie W
    Ann Hematol; 2024 Sep; 103(9):3315-3334. PubMed ID: 39017945
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene expression profiling and FDG-PET radiomics uncover radiometabolic signatures associated with outcome in DLBCL.
    Mazzara S; Travaini L; Botta F; Granata C; Motta G; Melle F; Fiori S; Tabanelli V; Vanazzi A; Ramadan S; Radice T; Raimondi S; Lo Presti G; Ferrari ME; Jereczek-Fossa BA; Tarella C; Ceci F; Pileri S; Derenzini E
    Blood Adv; 2023 Feb; 7(4):630-643. PubMed ID: 36806558
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined relapsed or refractory diffuse large B-cell lymphoma.
    Lenz G; Hawkes E; Verhoef G; Haioun C; Thye Lim S; Seog Heo D; Ardeshna K; Chong G; Haaber J; Shi W; Gorbatchevsky I; Lippert S; Hiemeyer F; Piraino P; Beckmann G; Peña C; Buvaylo V; Childs BH; Salles G
    Leukemia; 2020 Aug; 34(8):2184-2197. PubMed ID: 32060403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.